Business Trends– category –
-
MDPI Review Highlights Lipid Nanoparticles (LNPs) as Key to Rapid Antiviral Strategies for Pandemic Preparedness
MDPI International Overview A new MDPI review elaborates on nanoparticle-mediated antiviral strategies, emphasizing lipid nanoparticle (LNP) systems for their rapid response and efficient nucleic acid delivery in pandemic preparedness. N... -
FDA Manufacturing PreCheck Pilot Program Selects 7 Companies Including Cellares to Streamline and Expedite Cell Therapy Manufacturing Processes
RegMedNet UK Overview The FDA has selected seven companies, including Cellares Corp, FUJIFILM Biotechnologies, and Kriya Therapeutics, for its "Manufacturing PreCheck Pilot Program," designed to streamline cell and gene therapy manufactu... -
FDA Issues Over Six Warning Letters for Unapproved Exosome Therapies in US, Citing Illegal Sales and Unsubstantiated Claims (2024-2026)
Medical Spa Locator USA Overview As of June 2026, no injectable exosome products have received FDA approval in the United States. The FDA has issued over six warning letters between 2024 and 2026 to manufacturers and distributors selling... -
Australian iCamuno Biotherapeutics Launches Clinical Trial for Parkinson’s with ‘Hypoimmune Neural Cell Therapy’ Avoiding Immunosuppression
News Hub (Australia) Australia Overview Supported by A$4.6 million from the Australian government's Medical Research Future Fund, iCamuno Biotherapeutics has initiated a five-year research program to evaluate a novel stem cell therapy fo... -
Fate Therapeutics to Present iPSC-Derived Cell Immunotherapy Pipeline Progress at Investor Conferences
Fate Therapeutics, Inc. USA Overview Fate Therapeutics announced its participation in several upcoming investor conferences during Q3 2026. The clinical-stage biopharmaceutical company focuses on developing innovative 'off-the-shelf' iPS... -
Vertex’s CRISPR Gene Therapy CASGEVY Gains Expanded FDA Approval for Sickle Cell Disease and Beta Thalassemia in Children Ages 2 and Older
Vertex Pharmaceuticals USA Overview Vertex Pharmaceuticals announced the US FDA has approved an expanded indication for its gene therapy, CASGEVY® (exagamglogene autotemcel), for treating sickle cell disease or transfusion-dependent beta... -
UniXell’s iPSC-Derived Parkinson’s Therapy UX-DA003 Cleared for US Clinical Trials by FDA
Parkinson's News Today USA Overview UniXell Biotechnology has received FDA Investigational New Drug (IND) clearance for UX-DA003, an allogeneic iPSC-derived dopaminergic neural progenitor cell therapy for Parkinson's disease, enabling th... -
CAR T-Cell Therapy Expands to Autoimmune Diseases: Preliminary Data Reported from ~300 CD19-Targeted Treatments
RheumNow.com USA Overview CAR T-cell therapy is now being actively investigated not only for specific blood cancers but also as a treatment for autoimmune diseases such as systemic lupus erythematosus (SLE). As of May 2026, preliminary d... -
Exosome Clinical Trials Hit ~90 Globally in 2026: Advancing Regenerative Medicine, Diagnostic Biomarkers, and Drug Delivery
OmniGenix USA Overview A new peer-reviewed analysis in 2026 reveals approximately 90 exosome-related human clinical trials registered globally, showcasing diverse applications from cancer diagnostics to joint repair. Exosomes are being i... -
HCA Healthcare Announces Promising Results for CRISPR Gene Therapy Exa-cel in Pediatric Sickle Cell Disease and Beta-Thalassemia Patients
HCA Healthcare USA Overview HCA Healthcare has announced findings from a New England Journal of Medicine study, sponsored by Vertex Pharmaceuticals, demonstrating that the CRISPR gene-editing therapy exa-cel shows promising results in pe...
